sitagliptin

(redirected from Januvia)
Also found in: Medical.

sit·ag·lip·tin

 (sĭt′ə-glĭp′tn)
n.
An oral hypoglycemic drug, C16H15F6N5O, used in its phosphate form to treat type 2 diabetes.

[sita-, of unknown origin + -gliptin, hypoglycemic drug suffix; see saxagliptin.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Translations

sitagliptin

n sitagliptina
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
Biopharmaceutical company Avanir Pharmaceuticals Inc (NasdaqGS:AVNR) said on Monday that it has signed an exclusive, diabetes multi-year agreement with Merck (NYSE:MRK) for JANUVIA.
M2 EQUITYBITES-August 13, 2013-Avanir Pharmaceuticals executes diabetes co-promotion agreement with Merck for JANUVIA in the US(C)2013 M2 COMMUNICATIONS http://www.m2.com
Januvia sales were $1.1 billion in the quarter, up 18%.
Two other DPP-4 inhibitors have been previously approved for the same indication: sitagliptin (Januvia) and saxagliptin (Onglyza).
The companies hope Onglyza will carve out substantial sales by competing against Merck & Co.'s blockbuster drug, Januvia, which sold $1.4 billion worldwide in 2008.
Orally administered sitagliptin (Januvia) was approved in 2006 for use as monotherapy or in combination with metformin or thiazolidinedione for patients who have type 2 diabetes.
According to the contract, Merck, through a subsidiary, and Pfizer will work on the development and marketing of ertugliflozin and ertugliflozin-containing fixed-dose combinations with metformin and Januvia (sitagliptin) tablets.
Comments: Pharmaceuticals sales were up 3%, driven by Januvia, up 24% to $919 million, Victrelis sales of $111 million, Janumet, up 29% to $392 million, Gardasil, up 33% to $284 million, Zostavax, up 68% to $76 million, and Isentress, up 15% to $337 million.
Two other DPP-4 inhibitors have been previously approved for the same indication - sitagliptin (Januvia) and saxagliptin (Onglyza).
(San Diego CA) and Eli Lilly & Co.'s (Indianapolis IN) high-profile experimental once-weekly injectable diabetes drug proved superior to the widely used medicines Actos and Januvia in a clinical trial, according to data presented last week.
Merck also markets sita- gliptin as Januvia for the same disease.